Zacks Investment Research Downgrades Advanz Pharma (OTCMKTS:CXRXF) to Hold

Zacks Investment Research lowered shares of Advanz Pharma (OTCMKTS:CXRXF) from a buy rating to a hold rating in a research note published on Monday, reports.

According to Zacks, “Advanz Pharma Corp. is a specialty pharmaceutical company. It operates primarily in Bridgetown, Barbados; London, England and Mumbai, through its subsidiaries. Advanz Pharma Corp., formerly known as Concordia International Corp., is based in LONDON, UNITED KINGDOM. “

Separately, ValuEngine cut shares of Zumiez from a hold rating to a sell rating in a research report on Tuesday, July 2nd.

OTCMKTS:CXRXF opened at $14.69 on Monday. The company has a debt-to-equity ratio of 6.47, a current ratio of 2.01 and a quick ratio of 1.71. The business’s fifty day moving average is $15.59. The firm has a market capitalization of $718.49 million, a PE ratio of 1.25 and a beta of 0.50. Advanz Pharma has a fifty-two week low of $12.72 and a fifty-two week high of $60.99.

Advanz Pharma (OTCMKTS:CXRXF) last posted its quarterly earnings data on Friday, May 10th. The company reported ($0.16) earnings per share for the quarter. The business had revenue of $135.64 million for the quarter. Equities research analysts predict that Advanz Pharma will post -1.58 earnings per share for the current year.

About Advanz Pharma

ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

Further Reading: How to invest in a bear market

Get a free copy of the Zacks research report on Advanz Pharma (CXRXF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Advanz Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanz Pharma and related companies with's FREE daily email newsletter.